Description: Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
Home Page: www.citiuspharma.com
CTXR Technical Analysis
11 Commerce Drive
Cranford,
NJ
07016
United States
Phone:
908 967 6677
Officers
| Name | Title |
|---|---|
| Mr. Leonard L. Mazur | Co-Founder, CEO, Chairman & Sec. |
| Mr. Myron Z. Holubiak | Co-Founder & Exec. Vice Chairman |
| Mr. Jaime Bartushak | Chief Bus. Officer, CFO & Chief Accounting Officer |
| Dr. Myron S. Czuczman M.D. | Exec. VP & Chief Medical Officer |
| Mr. Gary F. Talarico | Exec. VP of Operations |
| Ms. Ilanit Allen | VP of Investor Relations & Corp. Communications |
| Dr. Alan Lader Ph.D. | Sr. VP & Head of Clinical Operations and Quality Assurance |
| Mr. Dhananjay G. Wadekar | Sr. VP of Bus. Strategy |
| Mr. Kelly Creighton Ph.D. | Exec. VP of Chemistry, Manufacturing & Controls |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 1.2887 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5048 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2017-07-06 |
| Fiscal Year End: | September |
| Full Time Employees: | 0 |